Home › Companies › Pharmaceuticals and biotechnology › Sweden
Is IRLAB Therapeutics AB stock halal?
Thresholds exceeded under all standards, and the strict view excludes it.
This verdict follows the median view, that of AAOIFI Standard No. 21. It is based on the financial statements for the fiscal year ended 12/31/2024.
The ratios
| Criterion | Measure | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 39.3% of total assets | 30% | threshold exceeded |
| Interest-bearing investments | 49.1% of total assets | 30% | threshold exceeded |
| Impermissible income | not published | 5% | to be verified |
Standard: Total assets, 30% threshold.
The three views
- Median view, our reference : the company is excluded.
- Strictest view : the company is excluded, because it borrows or invests at interest.
- Most lenient view : the company is excluded.
Business activity
Recherche et développement de traitements pour les patients atteints de la maladie de Parkinson
Financial statements read
Fiscal year ended 12/31/2024, in millions of SEK. Source: Annual report of IRLAB Therapeutics AB (ESEF format), fiscal year ended 2024-12-31.
What could not be verified
- Market capitalization: missing from the filed financial statements, so the AAOIFI ratio is not computed; tolerance is assessed on total assets.
- Interest received: amount not isolated in the filed financial statements.
- Financial statements for the fiscal year ended 12/31/2024: the next annual report was not in the database on the day of reading.
- Activity classified automatically from the "nature of activities" note of the annual report, without human review: to be confirmed.
- Figures read automatically and not reviewed by a human.
In the same sector
- ELI LILLY & Co Questionable
- JOHNSON & JOHNSON Permitted
- AbbVie Inc. Permitted
- Merck & Co., Inc. Permitted
- AMGEN INC Prohibited
- GILEAD SCIENCES, INC. Permitted
- ABBOTT LABORATORIES Permitted
- PFIZER INC Questionable
Compliance comparison only: no opinion on the value of these securities.
General information: neither investment advice nor a fatwa. Verdict calculated by published rules, from financial statements read automatically and not reviewed by a human. Read the methodology